Henning Willers is an Oncology physician affiliated with Massachusetts General Hospital. OpenAlex indexes 364 publications with 7,731 citations (h-index 53); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
75 Francis St
Boston, MA 021156106
Telephone
617-732-5500Provider last certified this registry record 9 Jan 2026.
Clinical trials
- Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer
Sponsor: Massachusetts General Hospital
- A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC
Sponsor: Massachusetts General Hospital
- Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer
Sponsor: Massachusetts General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
100%Corticosteroid100%Symbicort100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2018–2022 per NIH RePORTER. The latest:
- High-Throughput Screening and Validation of Molecular Targeted Chemoradiosensitizers
Massachusetts General Hospital
FY2022$554,744U01CA220714 - High-Throughput Screening and Validation of Molecular Targeted Chemoradiosensitizers
Massachusetts General Hospital
FY2021$753,506U01CA220714 - High-Throughput Screening and Validation of Molecular Targeted Chemoradiosensitizers
Massachusetts General Hospital
FY2020$616,064U01CA220714
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
International Journal of Radiation Oncology*Biology*Physics
2020 - Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer
Clinical Cancer Research
2019 - Modelling variable proton relative biological effectiveness for treatment planning
British Journal of Radiology
2019
Similar KOLs
Other experts from the same institution or the same specialty.
James Januzzi, MD
Massachusetts General Hospital
Maurizio Fava, MD
Massachusetts General Hospital
Steven Greenberg, MD
Massachusetts General Hospital
David Scadden, MD
Massachusetts General Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”